Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Upgraded at Hsbc Global Res

Hsbc Global Res upgraded shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Free Report) from a hold rating to a strong-buy rating in a report released on Wednesday morning,Zacks.com reports.

A number of other research analysts also recently commented on the stock. Kepler Capital Markets raised shares of Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a report on Wednesday, June 11th. Wall Street Zen raised shares of Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a report on Friday, June 6th. Finally, The Goldman Sachs Group raised shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research report on Thursday, June 5th. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy".

Bayer Aktiengesellschaft Price Performance

Shares of OTCMKTS BAYRY traded up $0.04 during mid-day trading on Wednesday, hitting $7.91. 566,277 shares of the company's stock traded hands, compared to its average volume of 804,994. The company has a debt-to-equity ratio of 1.19, a current ratio of 1.32 and a quick ratio of 0.81. Bayer Aktiengesellschaft has a 1 year low of $4.79 and a 1 year high of $8.58. The company's 50-day moving average is $6.72 and its two-hundred day moving average is $5.99. The company has a market capitalization of $31.08 billion, a P/E ratio of -30.42 and a beta of 0.85.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported $0.65 EPS for the quarter, beating analysts' consensus estimates of $0.63 by $0.02. Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive return on equity of 16.90%. The firm had revenue of $15.27 billion during the quarter, compared to the consensus estimate of $13.39 billion. On average, equities analysts anticipate that Bayer Aktiengesellschaft will post 1.31 EPS for the current fiscal year.

Bayer Aktiengesellschaft Increases Dividend

The firm also recently disclosed a dividend, which was paid on Monday, May 12th. Shareholders of record on Wednesday, April 30th were given a $0.0224 dividend. This represents a yield of 0.38%. The ex-dividend date was Tuesday, April 29th. This is an increase from Bayer Aktiengesellschaft's previous dividend of $0.02. Bayer Aktiengesellschaft's dividend payout ratio is -2.17%.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.